BofA Securities Reiterates Buy Rating on Medtronic, Inc. (MDT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to BofA Securities Reiterates Buy Rating on Medtronic, Inc. (MDT)
July 11, 2025 12:26 PM EDT
Goldman Sachs analyst David Roman reiterated a Sell rating and $78.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "On Thursday, July 10th, the Centers for Medicare and Medicaid Services (CMS) released a proposed Decision Memo to cover Renal Denervation (RDN) -- either radiofrequency (Medtronic) or ultrasound-based (Recor Medical, a subsidiary of... More
July 11, 2025 8:22 AM EDT
Raymond James analyst Jayson Bedford reiterated a Market Perform rating on Medtronic, Inc. (NYSE: MDT).
The analyst comments "CMS released its proposed National Coverage Determination (NCD) for Renal Denervation (RDN) last night (here). An NCD provides necessary scope around clinical eligibility for reimbursement purposes. The timeline was expected (on/before July 11). This document triggers another 30-day comment period, culminating with a final NCD expected to be published on/around October 8, 2025. Punchline: We believe the document reads well with no unexpected restrictions. CMSs inclusion threshold of 140 mmHg ambulatory blood pressure (which we believe equates... More
